News | January 31, 2025
Strides reports 14.6% growth in Q3 FY25 revenue
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region
PAT after MI is Rs. 41 crore which is 162% increase
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Subscribe To Our Newsletter & Stay Updated
